Green preparation and evaluation of the anti‐psoriatic activity of vesicular elastic nanocarriers of kojic acid from Aspergillus oryzae N12: Repurposing of a dermo‐cosmetic lead

• Published in: Archiv der Pharmazie (Weinheim) 2024-11, Vol.357 (11), p.e2400410-n/a
• Main Authors: Moussa, Ashaimaa Y., Abbas, Haidy, Zewail, Mariam, Gaafar, Passent M. E., Ibrahim, Nehal
• Format: Article
• Language: English
• Subjects: Acids; Administration, Cutaneous; Animals; Aspergillus oryzae; Drug Carriers - chemistry; Drug Liberation; Drug Repositioning; Humans; kojic acid; Male; Mice; molecular docking; Nanoparticles - chemistry; Particle Size; Psoriasis; Psoriasis - drug therapy; Psoriasis - pathology; Pyrones - administration & dosage; Pyrones - chemical synthesis; Pyrones - chemistry; Pyrones - pharmacology; spanlastics
• ISSN: 0365-6233; 1521-4184; 1521-4184
• DOI: 10.1002/ardp.202400410

Psoriasis is a skin disorder characterized by impaired epidermal differentiation that is regularly treated by systemic drugs with undesirable side effects. Based on its anti‐inflammatory, antiproliferative and anti‐melanoma attributes, the fungal metabolite kojic acid represents an attractive candidate for anti‐psoriatic research. The present work aims to investigate an efficient topical bio‐friendly vesicular system loaded with kojic acid isolated from Aspergillus oryzae as an alternative way for the management of psoriasis to avoid systemic toxicity. Kojic acid‐loaded spanlastics were prepared by ethanol injection technique, employing span 60 along with brij 35 and cremophor rh40 as edge activators, with the complete in vitro characterization of the developed nanoplatform. The selected formulation displayed a spherical morphology, an optimum particle size of 234.2 ± 1.65 nm, high entrapment efficiency (87.4% ± 0.84%) and significant sustained drug release compared with the drug solution. In vivo studies highlighted the superior relief of psoriasis symptoms and the ability to maintain healthy skin with the least changes in mRNA expression of inflammatory cytokines, achieved by the developed nanoplatform compared to kojic acid solution. Moreover, the in vivo histopathological studies confirmed the safety of the topically applied spanlastics. In addition, the molecular mechanism was approached through in vitro assessment of cathepsin S and PDE‐4 inhibitory activities and in silico investigation of kojic acid docking in several anti‐psoriatic drug targets. Our results suggest that a topically applied vesicular system loaded with kojic acid could lead to an expansion in the dermo‐cosmetic use of kojic acid as a natural bio‐friendly alternative for systemic anti‐psoriatic drugs. A topical bio‐friendly vesicular system loaded with kojic acid is investigated as an alternative way for the management of psoriasis to avoid systemic toxicity. The kojic acid‐loaded spanlastics displayed spherical morphology, high entrapment efficiency, and significant sustained drug release compared with the drug solution.